Login
$DRMA
$0.87 +$0.12 (15.85%) Close

Company Executives

Officer Age In this role Joined Pay Source
Gerald T. Proehl Also a director
President, Chief Executive Officer and Chairman
67 Not stated Not stated Not reported
Kyri K. Van Hoose
Senior Vice President, Chief Financial Officer
48 Since 2021
5 years
Not stated Not reported
Christopher J. Nardo
Senior Vice President, Chief Development Officer
61 Since 2022
4 years
Not stated Not reported
Maria Bedoya Toro Munera
Senior Vice President, Regulatory Affairs & Quality Assurance
74 Since 2016
10 years
Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
Not stated
the proxy does not say
Average tenure
7.6 years
from year joined
CEO also chairs the board
Yes
Gerald T. Proehl
Director Age On board Independent Committees Other public boards Pay Source
Gerald T. Proehl
67 2014
12 years
Not stated None stated Tenax Therapeutics, Inc. Paid as CEO
David Hale
77 2014
12 years
Not stated
Compensation Committee
None stated Not stated
Steven J. Mento, Ph.D.
74 2021
5 years
Not stated
Audit Committee
Histogen Inc. Not stated
Brittany Bradrick
56 2022
4 years
Not stated
Audit Committee
Spectrum Pharmaceuticals, Inc. Not stated
Wendell Wierenga, Ph.D.
78 2016
10 years
Not stated
Compensation Committee · Chair
Crinetics Pharmaceuticals, Inc. Not stated
Kathleen Scott
57 2021
5 years
Not stated
Audit Committee · Chair
NKGen Biotech, Inc. Not stated
Andrew Sandler, M.D.
61 2021
5 years
Not stated
Nominating and Corporate Governance Committee
None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Apr 17, 2026
Company insiders, including the Chief Executive Officer, Chief Financial Officer and certain members of management
Chief Executive Officer, Chief Financial Officer and certain members of our management
Approximately $1,500,000

Company insiders purchased Shares and Common Warrants in the Private Placement at the same price paid by other investors.

Gerald T. Proehl
President, Chief Executive Officer, and Chairman
Amount not stated

Holds January Warrants, through Proehl Investment Ventures, exercisable for 78,740 shares, subject to the proposed repricing.

Kyri K. Van Hoose
Chief Financial Officer
Amount not stated

Holds January Warrants exercisable for 7,874 shares, subject to the proposed repricing.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support